Placebo response in clinical randomized trials of analgesics in migraine

Lars Bendtsen, P. Mattsson, J. A. Zwart, Richard B. Lipton

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The objective was to assess the placebo response in randomized clinical trials of analgesics in the treatment of migraine attacks. We included placebo-controlled studies that used the criteria of the International Headache Society for the diagnosis of migraine and headache response as the primary efficacy parameter. In the 11 studies that qualified for inclusion, headache response occurred after placebo treatment in 7-50% of the migraineurs with an average placebo response rate of 30% (95% confidence interval (CI) 23-36). Two hours after treatment with placebo an average of 9% (95% CI 7-12, range 7-17%) of the patients were found to be pain free. In conclusion, the average headache response rate to placebo was 30% in randomized clinical trials of analgesics in migraine with a tremendous variation among studies. Placebo response rates vary with the choice of primary efficacy measure as well as patient characteristics and study design.

Original languageEnglish (US)
Pages (from-to)487-490
Number of pages4
JournalCephalalgia
Volume23
Issue number7
DOIs
StatePublished - Sep 2003

Fingerprint

Migraine Disorders
Analgesics
Randomized Controlled Trials
Placebos
Headache
Confidence Intervals
Therapeutics

Keywords

  • Analgesics
  • Clinical trials
  • Migraine
  • Placebo response

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Placebo response in clinical randomized trials of analgesics in migraine. / Bendtsen, Lars; Mattsson, P.; Zwart, J. A.; Lipton, Richard B.

In: Cephalalgia, Vol. 23, No. 7, 09.2003, p. 487-490.

Research output: Contribution to journalArticle

Bendtsen, Lars ; Mattsson, P. ; Zwart, J. A. ; Lipton, Richard B. / Placebo response in clinical randomized trials of analgesics in migraine. In: Cephalalgia. 2003 ; Vol. 23, No. 7. pp. 487-490.
@article{ce9b09f631ef4c76b446367b86bc022c,
title = "Placebo response in clinical randomized trials of analgesics in migraine",
abstract = "The objective was to assess the placebo response in randomized clinical trials of analgesics in the treatment of migraine attacks. We included placebo-controlled studies that used the criteria of the International Headache Society for the diagnosis of migraine and headache response as the primary efficacy parameter. In the 11 studies that qualified for inclusion, headache response occurred after placebo treatment in 7-50{\%} of the migraineurs with an average placebo response rate of 30{\%} (95{\%} confidence interval (CI) 23-36). Two hours after treatment with placebo an average of 9{\%} (95{\%} CI 7-12, range 7-17{\%}) of the patients were found to be pain free. In conclusion, the average headache response rate to placebo was 30{\%} in randomized clinical trials of analgesics in migraine with a tremendous variation among studies. Placebo response rates vary with the choice of primary efficacy measure as well as patient characteristics and study design.",
keywords = "Analgesics, Clinical trials, Migraine, Placebo response",
author = "Lars Bendtsen and P. Mattsson and Zwart, {J. A.} and Lipton, {Richard B.}",
year = "2003",
month = "9",
doi = "10.1046/j.1468-2982.2003.00528.x",
language = "English (US)",
volume = "23",
pages = "487--490",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Placebo response in clinical randomized trials of analgesics in migraine

AU - Bendtsen, Lars

AU - Mattsson, P.

AU - Zwart, J. A.

AU - Lipton, Richard B.

PY - 2003/9

Y1 - 2003/9

N2 - The objective was to assess the placebo response in randomized clinical trials of analgesics in the treatment of migraine attacks. We included placebo-controlled studies that used the criteria of the International Headache Society for the diagnosis of migraine and headache response as the primary efficacy parameter. In the 11 studies that qualified for inclusion, headache response occurred after placebo treatment in 7-50% of the migraineurs with an average placebo response rate of 30% (95% confidence interval (CI) 23-36). Two hours after treatment with placebo an average of 9% (95% CI 7-12, range 7-17%) of the patients were found to be pain free. In conclusion, the average headache response rate to placebo was 30% in randomized clinical trials of analgesics in migraine with a tremendous variation among studies. Placebo response rates vary with the choice of primary efficacy measure as well as patient characteristics and study design.

AB - The objective was to assess the placebo response in randomized clinical trials of analgesics in the treatment of migraine attacks. We included placebo-controlled studies that used the criteria of the International Headache Society for the diagnosis of migraine and headache response as the primary efficacy parameter. In the 11 studies that qualified for inclusion, headache response occurred after placebo treatment in 7-50% of the migraineurs with an average placebo response rate of 30% (95% confidence interval (CI) 23-36). Two hours after treatment with placebo an average of 9% (95% CI 7-12, range 7-17%) of the patients were found to be pain free. In conclusion, the average headache response rate to placebo was 30% in randomized clinical trials of analgesics in migraine with a tremendous variation among studies. Placebo response rates vary with the choice of primary efficacy measure as well as patient characteristics and study design.

KW - Analgesics

KW - Clinical trials

KW - Migraine

KW - Placebo response

UR - http://www.scopus.com/inward/record.url?scp=0141614060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141614060&partnerID=8YFLogxK

U2 - 10.1046/j.1468-2982.2003.00528.x

DO - 10.1046/j.1468-2982.2003.00528.x

M3 - Article

VL - 23

SP - 487

EP - 490

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 7

ER -